Recombinant Human Papillomavirus Nonavalent Vaccine in the Prevention of Cancers Caused by Human Papillomavirus

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2019 Jul 17

PMID 31308715

Citations 29

Authors

Zheng Quan Toh

Jennie Kosasih

Fiona M Russell

Suzanne M Garland

Edward K Mulholland

Paul V Licciardi

Affiliations

Soon will be listed here.

Abstract

Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated high vaccine efficacy (>90%) against cervical, vulvar, and vaginal precancers caused by these additional types, and have shown comparable immunogenicity to the shared genotypes to quadrivalent HPV vaccine (4vHPV). Vaccine efficacy and antibody responses for 9vHPV are found to persist for at least five years while longer-term observational studies are ongoing to monitor long-term vaccine effectiveness. The implementation of 9vHPV has the potential to prevent up to 93% of cervical cancer cases, as well as a significant proportion of other HPV-related anogenital cancers. This review article summarizes the current evidence for 9vHPV in terms of vaccine efficacy against HPV infection and related anogenital precancers, safety, and immunogenicity, as well as discussing the potential impact of this vaccine on the cervical cancer burden globally.

Citing Articles

Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine.

Quang C, Anderson J, Russell F, Reyburn R, Ratu T, Tuivaga E Nat Commun. 2025; 16(1):2130.

PMID: 40032823 PMC: 11876628. DOI: 10.1038/s41467-025-57443-z.

Engineering Saccharomyces cerevisiae for medical applications.

Maneira C, Chamas A, Lackner G Microb Cell Fact. 2025; 24(1):12.

PMID: 39789534 PMC: 11720383. DOI: 10.1186/s12934-024-02625-5.

Exploring the Intricacies of Cervical Intraepithelial Neoplasia and Its Connection with HPV: A Narrative Review.

Karimi P, Reza Hosseini S, Mousavian Hiagh Z, Aboulhassanzadeh S, Asghari N, Aghazadeh H Iran J Public Health. 2025; 53(12):2671-2682.

PMID: 39759206 PMC: 11693788.

High frequency of alpha7-HPV in Colombian Caribbean coast women: cervical cancer screening analysis.

Arteaga-Pautt H, Bru-Cordero O, Ricardo-Caldera D, Espitia-Perez L, Aviles-Vergara P, Tovar-Acero C BMC Infect Dis. 2024; 24(1):539.

PMID: 38811877 PMC: 11137938. DOI: 10.1186/s12879-024-09410-0.

Human papillomavirus genotype distribution among women with and without cervical cancer: Implication for vaccination and screening in Ghana.

Nartey Y, Amo-Antwi K, Hill P, Dassah E, Asmah R, Nyarko K PLoS One. 2023; 18(1):e0280437.

PMID: 36656844 PMC: 9851533. DOI: 10.1371/journal.pone.0280437.

References

Frisch M, Biggar R, Goedert J . Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000; 92(18):1500-10. DOI: 10.1093/jnci/92.18.1500. View

Molano M, van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A . Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003; 158(5):486-94. DOI: 10.1093/aje/kwg171. View

Block S, Nolan T, Sattler C, Barr E, Giacoletti K, Marchant C . Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006; 118(5):2135-45. DOI: 10.1542/peds.2006-0461. View

. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356(19):1915-27. DOI: 10.1056/NEJMoa061741. View

Garland S, Hernandez-Avila M, Wheeler C, Perez G, Harper D, Leodolter S . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19):1928-43. DOI: 10.1056/NEJMoa061760. View

DSouza G, Kreimer A, Viscidi R, Pawlita M, Fakhry C, Koch W . Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007; 356(19):1944-56. DOI: 10.1056/NEJMoa065497. View

Pedersen C, Petaja T, Strauss G, Rumke H, Poder A, Richardus J . Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007; 40(6):564-71. DOI: 10.1016/j.jadohealth.2007.02.015. View

Petaja T, Keranen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M . Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2008; 44(1):33-40. DOI: 10.1016/j.jadohealth.2008.10.002. View

Garland S, Steben M, Sings H, James M, Lu S, Railkar R . Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009; 199(6):805-14. DOI: 10.1086/597071. View

10.

Wheeler C, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Perez G . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009; 199(7):936-44. DOI: 10.1086/597309. View

11.

Brown D, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Wheeler C . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009; 199(7):926-35. DOI: 10.1086/597307. View

12.

Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

13.

Einstein M, Baron M, Levin M, Chatterjee A, Edwards R, Zepp F . Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009; 5(10):705-19. DOI: 10.4161/hv.5.10.9518. View

14.

Marur S, DSouza G, Westra W, Forastiere A . HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010; 11(8):781-9. PMC: 5242182. DOI: 10.1016/S1470-2045(10)70017-6. View

15.

Larson D, Derkay C . Epidemiology of recurrent respiratory papillomatosis. APMIS. 2010; 118(6-7):450-4. DOI: 10.1111/j.1600-0463.2010.02619.x. View

16.

Dillner J, Kjaer S, Wheeler C, Sigurdsson K, Iversen O, Hernandez-Avila M . Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341:c3493. PMC: 2907480. DOI: 10.1136/bmj.c3493. View

17.

de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

18.

Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch F, de Sanjose S . Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202(12):1789-99. DOI: 10.1086/657321. View

19.

Kemp T, Hildesheim A, Safaeian M, Dauner J, Pan Y, Porras C . HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine. 2011; 29(11):2011-4. PMC: 3046309. DOI: 10.1016/j.vaccine.2011.01.001. View

20.

Garcon N, Wettendorff M, Van Mechelen M . Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther. 2011; 11(5):667-77. DOI: 10.1517/14712598.2011.573624. View